Non-ionic surfactant micelles are helpful for improving the diffusion of topically delivered drugs through the cornea. This study aimed to develop terbinafine hydrochloride (TH)-loaded micelles based on a soft non-ionic surfactant-macrogol 15 hydroxystearate (HS 15) and to investigate their in vivo cornea permeation. Briefly, 0.25% TH-loaded HS 15 micelles (TH-HNMs) were developed using a simple co-solvent method. Characterization of the TH-HNMs by Zetasizer and transmission electron microscopy (TEM) revealed that the spherical and discrete micellar droplets with a small size (13.22 ± 0.73 nm) and an electrically neutral surface (−2.15 ± 0.39 mV) were achieved. The drug entrapment efficiency of TH-HNMs was almost 100%. The release of TH from the micelles was pH dependent. 93.2 ± 3.4% of encapsulated TH was released from the micelles in the PBS at pH 5.0 within 6 h, but only 0.122 ± 0.020% of encapsulated TH was released in the PBS at pH 7.4 within the same release time. TH-HNMs possessed good physical stability in the pH neutral medium (pH 7.0).No obvious irritations were observed in rabbit eyes after ocular instillation of TH-HNMs. The in vivo corneal permeation study revealed that the TH-HNMs can penetrate into the corneal epithelium quickly and efficiently in mouse eyes. Good permeability was also noted in the stroma of mouse corneas with de-epithelialization. Compared with the TH oily solution, TH-HNMs delivered considerably increased levels of TH into rabbit corneas with or without de-epithelialization. In conclusion, the easily prepared, small, physically stable and biocompatible TH-HNMs with good ocular bioavailability hold great promise as an efficient carrier for topical ocular delivery of TH.
Introduction
Fungal keratitis is a severe sight-threatening corneal disease that primarily affects the corneal epithelium and stroma (Tuli, 2011) . Conventional eye drops remain the most widely utilized medication for the treatment of fungal keratitis (Prajna et al., 2010; Sharma et al., 2015) . However, these eye drops routinely have poor ocular bioavailability that results from the various anatomical and physiological barriers in the eye and the high molecular mass or hydrophobic properties of most antifungal agents (Chaurasia et al., 2015; Kaur et al., 2008) .
For successful treatment of this infection, prolonged and aggressive pharmaceutical therapy are typically adopted (Niki et al., 2014; Tuli, 2011) . To overcome these constraints, various colloidal carriers such as nanoparticles (Chandasana et al., 2014) , liposomes (Habib et al., 2010) , solid lipid nanoparticles (Mohanty et al., 2015) , nanoemulsions (Tayel et al., 2013) and polymeric micelles (Jaiswal et al., 2015) have been utilized for improving the ocular bioavailability of poorly soluble antifungal agents. The colloidal carriers hold great promise for revolutionizing the pharmacotherapy of fungal keratitis. However, the colloidal carriers perhaps penetrated through the whole corneal epithelium inefficiently, though they could improve the corneal drug absorption remarkably (De Campos et al., 2003; Zimmer et al., 1991) . They also face another common problem: drug release occasionally takes longer than the ocular residence time of the colloidal carriers themselves (Romero et al., 2016) . Whereas, the quick release of drug from the colloidal carriers always indicates severe drug leakage during the storage. So, the development of effective ocular preparations of antifungal agents for fungal keratitis continues to be a challenging task.
Non-ionic surfactant micelles (NMs), which can improve the diffusion of insoluble drugs through the cornea (Kuwano et al., 2002; Luschmann et al., 2013) , should be undoubtedly considered as a potential candidate of topically used ocular antifungal drug carriers. Non-ionic surfactants can form micelles when dissolved in water at concentrations above the critical micelle concentration (CMC). These surfactants possess several favorable advantages as topical ocular drug delivery systems, including corneal permeability promoting effects, good ocular tolerance and the formation of extremely small nanoscale droplets (Kaur and Smitha, 2002; Vaishya et al., 2014) . Specifically, the small size of micelles may facilitate their cellular uptake via adsorptivetype endocytosis (Qaddoumi et al., 2004) , which should be the primary mechanism for colloidal carriers penetrating into the corneal epithelium (De Campos et al., 2003; Pepić et al., 2013; Pleyer et al., 1995) . The smaller droplets are likely to be more permeable in the corneal stroma, which discriminates the macromolecules based on their size (Prausnitz and Noonan, 1998) .
HS 15 is a novel and soft non-ionic surfactant that is widely used to solubilize poorly soluble drugs (Alani et al., 2010; Liu et al., 2016) . HS 15 can form 13-to 14-nm micelles in aqueous media above its CMC (0.06-0.1 mM) at 37°C (Shubber et al., 2015) . The CMC and the size of HS 15 micelles do not appear to be influenced by the composition of biologically relevant buffers (HBSS-HEPES and PBS) or the temperature. Additionally, HS 15 also inhabits P-glycoprotein (efflux transporter), affects the cell membrane, opens tight junctions between epithelial cells, and thus potentially enhances drug absorption by transcellular and paracellular mechanisms (Brayden et al., 2012; Cornaire et al., 2004; Shubber et al., 2015) . HS 15 enhances the permeability of low molecular hydrophobic drugs and medium sized hydrophilic macromolecular drugs across the epithelia with low cytotoxicity (Alani et al., 2010; Shubber et al., 2015) .
TH is a poorly soluble synthetic allylamine antifungal agent that could effectively inhibit Fusarium species isolated from ocular tissues (Liang et al., 2009; Xuguang et al., 2007) . In this study, the micelles based on HS 15 were used to deliver TH into the cornea. TH-HNMs, which possessed adequately small size and high drug loading capacity, were expected to penetrate the cornea readily and efficiently. TH-HNMs were characterized for particle size, zeta potential, morphology, drug entrapment efficiency, in vitro drug release and ocular irritation. The corneal permeation of the TH-HNMs was evaluated in mouse and rabbit eyes with or without corneal de-epithelialization after ocular instillation. New Zealand albino rabbits weighing 1.8 to 2.3 kg were purchased from Hualan Biological Engineering, Inc. (Xinxiang, Henan, China). Male C57BL/6 mice that were pathogen-free grade and free of clinically observable ocular surface disease were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). All of the mice were used at 4 months of age. All animal care and experimental protocols were approved by the Ethical Committee of Experimental Animal Care of Henan Eye Institute and performed in compliance with National Institutes of Health guidelines and the Association for Research in Vision and Ophthalmology resolution concerning the use of animals in ophthalmological research.
Materials and methods

Materials
Preparation of TH-HNMs
TH-HNMs were prepared using a simple co-solvent method. Glycerol (2.5 g), TH (0.25 g) and HS 15 (1.0 g) were mixed and heated until TH was completely dissolved. Then, 90 ml of hot water (60°C) containing ethylparaben (0.03% w/v) was quickly added and vigorously stirred until a clear micellar solution was achieved. After cooling to ambient temperature, the pH value of the diluted samples was adjusted to 7.0 ± 0.1 using sodium hydroxide solution (2.5%, w/v). Finally, the samples were diluted to 100 ml. The TH micelle solution exhibited a transparent appearance with light blue opalescence. The final micellar solutions were filtered using GP syringe-driven filter units (0.22 μm, Merck Millipore, Cork, Ireland) for purification and sterilization.
FDA (0.005 g) was used to prepare FDA-labeled TH-HNMs according to the same method described above (F2) to investigate the corneal permeability of TH-HNMs in mouse eyes. Briefly, 0.5 ml of FDA-labeled TH-HNMs was washed thrice using an Ultra-4 Centrifugal Filter unit (MW cut-off: 50 kDa, Merck Millipore, Cork, Ireland) to remove the free FDA before administration. The FDA suspensions were prepared by a similar method without adding HS 15 and used as a control in the corneal permeability study in mouse eyes.
The oily preparation of TH was obtained by simply dissolving TH (0.25 g) in castor oil (100 ml) and used as a control in the ocular pharmacokinetics study in rabbit eyes.
Osmotic pressure, particle size and zeta potential
The osmotic pressure of TH-HNMs solution was determined by a freezing point osmometer (OSMOMAT 030, Gonotec GmbH, Berlin, Germany). 50 μl of TH-HNMs solution was used for the osmotic pressure determination.
Hydrodynamic droplet size, polydispersity index (PDI), and zeta potential of the TH-HNMs were measured using a Zetasizer (Nano-ZS90, Malvern Instruments, Worcestershire, UK). Disposable sizing cuvettes were used for particle size analysis. Light scattering was monitored at a 90°angle at 25°C. The size distribution data was based on intensity. The clear disposable fold capillary cells were used for zeta potential analysis at 25°C. All samples were measured without any dilution. The number of measurements was set to 3.
Transmission electron microscopy
Transmission electron micrographs were captured to visualize the shape of TH-HNMs. One drop of the micellar solution was loaded onto copper grids. Excess solution was removed with a filter paper. The micelles were negatively stained with phosphotungstic acid aqueous solution (2%, w/v) for 3 min. The loaded grids were examined under a transmission electron microscope (Joel JEM 1230, Tokyo, Japan).
Drug content and entrapment efficiency (EE)
The quantitative analysis of TH was performed with a Waters Alliance 2695 high-performance liquid chromatography system (HPLC) equipped with a 2487 Dual λ absence detector (Waters, Milford, MA. USA). A Waters XBridge® C18 column (3.5 μm, 2.1 mm × 50 mm) was used for chromatographic separations at 40°C. The mobile phase consisted of water and methanol (10:90, v/v) , and the flow rate was set at 0.7 ml/min (isocratic elution). The TH was detected at 224 nm.
The concentration of TH in the investigated micellar formulation was detected by HPLC after dilution with methanol. Ultra-4 Centrifugal Filter units (MW cut-off: 50 kDa) were used for separating free TH in the aqueous phase from the TH loaded micelles. Briefly, 1 ml of TH micelle solution was added to the sample reservoir and centrifuged (5810 R, Eppendorf, Germany) at 4000 rpm for 10 min. The filtrate was diluted with an equal volume of methanol for HPLC analysis. The entrapment efficiency (% EE) was calculated as follows: % EE = (C t -C f ) / C t × 100where C t is the total drug concentration, and C f is the concentration of free drug in the aqueous phase.
In vitro drug release studies
The solubility of TH in phosphate buffer solutions (PBS) with different pH value was determined before the drug release study. Aliquots (10 mg) of TH were added in 20 ml of PBS (pH 5.0), respectively. The TH suspensions were obtained after fully stirring. The pH value of the suspensions was adjusted to 5.0 ± 0.1, 6.0 ± 0.1 and 7.4 ± 0.1 using sodium hydroxide solution (2.5%, w/v),respectively. Twenty four hours later, the suspensions were filtered using GP syringe-driven filter units (0.22 μm) and the filtrate was thoroughly mixed with an equal volume of methanol. The mixture was analyzed by HPLC (Section 2.5).
The in vitro release of TH from the micelles was evaluated using a modified dialysis method (Bhatta et al., 2012) . Aliquots (2 ml) of investigated formulation were withdrawn and sealed in the dialysis bags (cellulose membrane, MW cut-off: 14 kDa). The bags were immersed in 100 ml of different PBS (pH 5.0, 6.0 and 7.4). The release studies were performed in an incubator shaker rotating at 150 rpm at 34°C. Aliquots (1 ml) of release medium were withdrawn and replaced with an equal volume of fresh PBS at predetermined time points (15 min, 30 min, 1 h, 2 h, 4 h, and 6 h). The amount of released TH was analyzed by HPLC (Section 2.5).
Short-term stability
The prepared samples were sealed in glass vials after filling nitrogen and stored at 4°C/25% RH, 25°C/60% RH, and 40°C/75% RH with protection from light. The particle size, drug content and %EE of the samples were assessed according to the methods described above (Sections 2.3 and 2.5) after preparation (day 0), 2 weeks, 1 month and 3 months.
Ocular irritation studies
Six New Zealand albino rabbits were used in the ocular irritation studies using a modified Draize test (Bhatta et al., 2012) . Briefly, 50 μl of the micellar formulation was instilled into the lower conjunctival culde-sac of the left eyes. The eyelids were kept closed for 10 s after instillation to prevent the loss of instilled solution. The right eyes were treated with normal saline and served as a control. At 1, 2, 4, 8, 24, 48 and 72 h after instillation, the eyelids, cornea, iris and conjunctiva of both sides were examined. Furthermore, the eyes were stained with fluorescein sodium and examined by a hand slit lamp to verify possible corneal lesions. If severe irritation or damage occurred, further observations were performed until the treated eyes had completely recovered. The congestion, edema and discharge of the conjunctiva were graded on scales ranging from 0 to 3, 0 to 4 and 0 to 3, respectively. Iris irritation was graded on a scale of 0 to 2. Corneal opacity was graded on a scale of 0 to 4 (Bhatta et al., 2012) . Irritation was evaluated by the average total scores using a four grades criterion: nonirritant, score 0-3; slightly irritant, score 4-8; moderately irritant, score 9-12; and severely irritant, score 13-16 (Li et al., 2014) .
Corneal permeation studies in mouse eyes
The corneal permeation of FDA-loaded TH-HNMs in the mouse eyes was examined using an LSM 780 NLO two-photon laser scanning fluorescence microscope system (Carl Zeiss, Jena, Germany) . The mice were anesthetized with an intraperitoneal injection of pentobarbital sodium (85 mg/kg body weight). And, 50 μl of tetracaine hydrochloride eye drops (0.5% w/v) was topically administrated to the left eye for topical anesthesia. Then, the corneal epithelium of the left eye was carefully removed with a disposable crescent scalpel. One hour after corneal de-epithelialization, the FDA-loaded TH-HNMs were instilled onto the cornea of the mouse eyes (both sides, at a time interval of 15 min). After administration, animals were maintained in a dark room before examination. The corneal distribution of FDA-loaded THHNMs was examined 30 and 60 min after administration. The treated eyes were rinsed with normal saline before observation. A × 20 waterimmersion objective (Plan-Apochromat, Numerical aperture [NA] 1/4 1.0) was used in this study. The excitation wavelength was set at 720 nm, and the laser intensity was set at 11%. The pinhole was set to the maximal opening. The central region of the cornea was scanned using a 2-μm z-axis step size to generate 3D data.
Pharmacokinetic studies in rabbit eyes
Seventy rabbits were evenly divided into two groups randomly, an experimental group (35 animals) and a control group (35 animals). Animals in experimental group were administrated with TH-NMs (both sides) and the control animals were administrated with oily TH (both sides). Both groups were evenly separated into seven time groups (5 animals in each group) randomly, respectively. Food and water were freely available during the experiment. The corneal epithelium of the left eyes was removed according to a previously published method (Tianyang et al., 2014) . Briefly, 50 μl of micellar formulation or oily TH was instilled into the lower cul-de-sac of the eyes (both sides, at a time interval of 1 min), and the eyelids were kept closed for 10 s after instillation. The animals were sacrificed via an injection of a lethal overdose of pentobarbital sodium solution (4%, w/v) into the ear vein at 5, 15, 30, 60, 120, 240 or 360 min after instillation. The eyes were then rinsed with normal saline. The aqueous humor was drawn by a disposable sterile syringe with a 26G needle (needling from the limbus). Subsequently, the corneas were cut off with an ophthalmic surgical scissor after making a little incision near the limbus with a surgical blade. The cut corneas were rinsed again with normal saline and the residual liquid was gently blotted up by a filter paper. Then, the collected corneas were precisely weighed and the collected aqueous humor was divided into aliquots of 100 μl. All of the tissue samples were stored at − 80 ± 10°C until analyzed.
For HPLC analysis, the collected cornea was weighed and cut into pieces and immersed in 0.4 ml methanol for 24 h at 4°C while being protected by nitrogen (Tianyang et al., 2014) . Then, 100 μl of collected aqueous humor was mixed with 200 μl of methanol, and the solution was incubated at room temperature for 30 min. The processed cornea and aqueous samples were centrifuged (MiniSpin® Plus, Eppendorf, Germany) at 12,000 rpm for 8 min, and the supernatant was collected for HPLC analysis. The bioanalytical methods for quantification of TH in cornea and aqueous humor were both validated for specificity, sensitivity, linearity, recovery, precision, accuracy, stability, and dilution integrity and successfully applied for determining the tissue samples of the pharmacokinetics study. The drug pharmacokinetic parameters in rabbit cornea and aqueous humor were calculated using DAS software Ver. 2.1.1 (Shanghai BioGuider Medicinal Technology Co., Ltd., Shanghai, China). The maximum concentration (C max ) of TH and the peak time (T max ) were presented as the detected value.
Results and discussion
Preparation and characterization of TH-HNMs
Glycerol was used as a co-solvent of TH and HS 15, thus avoiding the use of toxic or irritant organic solvents in the preparation of THHNMs. Clear micellar solutions can be obtained by simply mixing the TH and HS 15 glycerol co-solution with water. Glycerol was also used as an isotonicity regulator in TH micelle solutions. Thus, the glycerol did not require removal after preparation. The simple preparation procedure of TH-HNMs should be very suitable for its further industrialization. The osmotic pressure was 0.291 ± 0.007 Osmol/kg (n = 3). The mean concentration of TH in the formulations was 2.44 ± 0.04 mg/ml (n = 3). 97.6 ± 1.6% (n = 3) of added TH was recovered. The concentration of free TH in the aqueous phase was only 0.05 ± 0.01 μg/ ml (n = 3). The drug EE (%) of the TH-HNMs was 100.0 ± 0.0%. The high drug EE is attributed to its high hydrophobicity in the pH neutral medium. Additionally, the weight ratio of added TH to HS 15 was 1:4, indicating that HS 15 micelles possessed a very high TH loading capacity.
The mean hydrodynamic diameter of the developed TH-HNMs was 13.22 ± 0.73 nm with a low PDI (0.036 ± 0.011). The particle size of TH-HNMs visualized by TEM was consistent with the size obtained from the Zetasizer (Fig. 1) . The TH-HNM droplets were spherical in shape and lacked any signs of aggregation. The mean zeta potential of TH-HNM droplets was − 2.15 ± 0.39 mV. The slightly negative surface charge was a common feature of non-ionic surfactant micelles (Vaishya et al., 2014) . These approximately neutral micelle droplets potentially failed to prolong the precorneal residence time after topical administration. However, they should diffuse more easily in the corneal epithelium or in the corneal stroma (biological gels) compared to the positively charged colloidal carriers (De Campos et al., 2003; Lieleg and Ribbeck, 2011) . This feature should be helpful to improve the therapeutic effects of topically applied antifungal agents whose main targeting site was located in the corneal stroma.
In vitro drug-release
In this study, the release of TH from the HS 15 micelles was pHdependent (Fig. 2) . It should be attributed to the pH-dependent aqueous solubility of TH. The solubility of TH in pH 5.0, 6.0 and 7.4 PBS was 108.2 ± 2.4 μg/ml, 10.3 ± 0.44 μg/ml and 0.112 ± 0.015 μg/ml, respectively. 93.2 ± 3.2% of encapsulated TH released from the micelles in the PBS at pH 5.0 within 6 h. But the cumulative release rate of TH in the PBS at pH 7.4 was only 0.122 ± 0.020% within the same release time. These results suggested that the TH-HNMs can release drugs quickly in the acidic intracellular environment (endosomes or lysosomes) after being taken up by the cells through an endocytosis pathway (Pepić et al., 2013; Sun et al., 2015) . The low drug release rate in the neutral pH medium indicates a low drug leakage rate during the storage. These features could be very helpful for the long-term physical stability of TH-HNMs.
Short-term physical stability
The presented TH-HNMs exhibited good thermodynamics stability and a very low drug leakage rate during storage under different conditions. After 3 months of storage at 4°C, 25°C, and 40°C, the physical appearance of the stored micellar solutions was unaltered. No visual precipitates were observed in the formulations. The particle size and PDI of TH-HNM droplets exhibited no significant difference with the initial value ( Table 1 ). The total contents of TH all decreased as the storage times increased for three temperatures (Fig. 3) . The concentration of TH changed from the initial 2.44 ± 0.04 mg/ml to 2.40 ± 0.02 mg/ml after 3 months storage at 4°C. When stored at 25°C and 40°C, the reduction of TH content was significantly increased. Therefore, 4°C is the favorable storing condition for TH-HNMs. The initial value of %EE of TH-NMs was 100.0 ± 0.0%. There was no significant decrease in the drug entrapment efficiency of TH-NMs stored at all three temperatures as time went on. It indicated that almost no TH leaked from the micelles during the storage.
Ocular irritation
After ocular instillation of TH-HNM solution, no obvious irritation was observed in the cornea, conjunctiva or iris of the control and Fig. 1. Morphology (A) and size distribution (B) of the THHNMs. Fig. 2 . In vitro TH release profiles from the TH-HNMs under different pH conditions. Bars represent ± SD (n = 3).
Table 1
The particle size and polydispersity index (PDI) of TH-HNMs during storage under different conditions. Data represent mean ± SD (n = 3). experimentally treated eyes. The average total scores of irritation test were less than 2 at all time points (Fig. 4) . The fluorescent staining test revealed that corneal lesions did not occur throughout the experiment. The animals also showed no other abnormal reactions when they received the investigated micellar formulation.
Corneal permeation studies in mouse eyes
For the eyes with intact corneal epithelium, the fluorescence signals are mostly located in the apical layers of corneal epithelium at 30 min after instillation of the FDA-loaded TH-HNMs (Fig. 5) . The fluorescence signals in the deep epithelial layers considerably reduced. Fluorescence in the corneal stroma was minimally observed. As time increased, the fluorescence intensity in the deep layers of epithelium and stroma increased. Strong fluorescence signals were observed in the entire epithelium. However, fluorescence signals in the stroma remained considerably weaker compared with the epithelial layers. After instillation of FDA suspensions, visible fluorescent signals were only observed in a few superficial layers of the epithelium at both predetermined time points.
The micellar drug carriers were supposed to cross the epithelial layers using a transcellular pathway (Guo et al., 2015; Pepić et al., 2013) . Its permeation to the deep layers most likely involves a transcytosis mechanism. Li demonstrated that the micelles entered Caco-2 cells (monolayer) at the apical surface via endocytosis and subsequently leave the cells via exocytosis at basolateral surface in an intact form (Li et al., 2012) . In view of this and the shallow penetration depth of free FDA, the improvement of corneal permeation of encapsulated FDA should be mostly attributed to the transcytosis of intact micelle droplets by adjacent epithelial cells rather than the passive diffusion of the released FDA molecules (Qaddoumi et al., 2004) . However, the absorbed TH-HNMs were mostly located in the epithelial layers, especially in the apical layers (Fig. 5) . These results suggest that the apical corneal epithelial cells may internalize the TH-HNMs quickly and efficiently via an endocytosis pathway but are much less efficient at transporting them into deeper layers by transcytosis mechanisms. Thus, the corneal epithelium can be regarded as a crucial penetrating barrier and a drug reservoir for the micellar formulations.
Fungal keratitis always causes serious corneal ulcers. Repeated debridement of the ulcer before topical administration is strongly recommended to enhance drug corneal penetration (Tuli, 2011) . The corneal stroma under the ulcer can be directly exposed to the topically Fig. 3 . TH concentration in the micelle formulations during storage under different conditions. Bars represent ± SD (n = 3), *P < 0.05/**P < 0.01. applied antifungal preparations after simple debridement. Thus, more attention should be paid to the diffusion properties of antifungal colloidal carriers in corneal stroma after corneal de-epithelialization. Thus, mice subject to corneal epithelium debridement were used to investigate the permeation of TH-HNMs into the corneal stroma.
For the de-epithelialized mouse eyes, the FDA-loaded TH-HNMs exhibited good permeability in the corneal stroma. Fluorescent signals were observed in the corneal stroma, corneal endothelium and aqueous humor after topical instillation of the FDA-loaded TH-HNMs (Fig. 6a  and b) . These results indicated that the TH-HNMs can readily penetrate trough the corneal stroma of the mouse eyes. After administering FDA suspensions, the FDA failed to penetrate into corneal endothelium and aqueous humor. However, FDA reached the deep layer of corneal stroma.
The corneal stroma, which comprises 90% of the corneal thickness, consists of hundreds of tightly stacked lamellae. Each lamella contains a few scattered keratocytes, parallel collagen fibrils and orthogonally attached proteoglycans (Meek and Boote, 2004) . These hydrated collagen fibrils and proteoglycans form a dense and well-organized, mutually interconnected extracellular network anchoring the limbus Fig. 6. a) In vivo two-photon microscopy images of corneal cross-sections at 30 min and 60 min after the instillation of the FDA suspensions (A) and FDA-loaded TH-HNMs (B) onto de-epithelialized C57BL/6 mouse corneas. b) In vivo three dimension two-photon microscopy images of corneas at 30 min and 60 min after the instillation of the FDA suspensions (A) and FDAloaded TH-HNMs (B) onto de-epithelialized C57BL/6 mouse corneas. Fig. 7 . Concentration-time profiles of TH in normal rabbit corneas following topical instillation of the TH-HNMs and oily TH. Bars represent ± SD (n = 5), **P < 0.01.
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European Journal of Pharmaceutical Sciences 109 (2017) 288-296 (Müller et al., 2004) . The physiological roles of this highly hydrated network are not confined to mechanical and optical functions. Lamellae may also act as a permeability barrier that can discriminate particles based on their size or their surface properties. The mesh size of the hydrated network in the corneal stroma of human eyes is approximately 20 to 40 nm (Meek and Boote, 2004; Müller et al., 2004) . Therefore, a large part of colloidal carriers probably cannot penetrate through the corneal stroma given their large size. The impact of the particle size on the corneal absorption and distribution should be fully considered during the development of topically used ocular colloidal carriers for antifungal agents. The mobility of positively charged particles in the corneal stroma may also be suppressed by electrostatic interactions between the diffusing particles and the negatively charged collagen fibrils, PGs or other biopolymers (Lieleg et al., 2010; Lieleg and Ribbeck, 2011) . Thus, the good permeability of TH-HNMs in the corneal stroma should depend on their small size and almost electroneutral surface.
Pharmacokinetic studies in rabbit eyes
The surfactant micelles undoubtedly could enhance the ocular bioavailability of insoluble drug (Vaishya et al., 2014) . However, the ocular pharmacokinetics of these micelles indicated that these micellar formulations transported very few loaded drugs into the corneal stroma, aqueous humor or iris-ciliary body after topical instillation (Guo et al., 2015; Kuwano et al., 2002; Vaishya et al., 2014 ). The corneal stroma drug level was even less than 1/10 of the corneal epithelium drug level after topical instillation of CSA micelles (Kuwano et al., 2002) . To quantitatively investigate the penetration of TH-HNMs through the cornea with or without epithelium, drug pharmacokinetics in cornea and aqueous humor were evaluated in rabbit eyes. Repeated administration was adopted to increase the aqueous humor drug level for easy and accurate quantitative detection.
From Fig. 7 , the drug concentrations in normal rabbit corneas treated with TH-HNMs were significantly increased compared with those for oily TH at all time points. The AUC 0-360 min for TH-HNMs in the normal cornea increased 3.9-fold compared with oily TH (Table 2) . However, the significant enhancement of TH-HNMs bioavailability in normal cornea did not result in a corresponding improvement of aqueous humor drug levels. The aqueous humor drug levels for TH-HNMs and oily TH were both less than the lower limit of quantitation (LLOQ) although repeated administration was adopted in this study. TH-HNMs did not efficiently penetrate through the entire intact rabbit cornea. It indicated that most of the absorbed micelles might be trapped in the superficial epithelial cell layers because of their inefficient transcellular transportation. These findings were consistent with the distribution features of FDA-loaded TH-HNMs in the mouse corneas presented above and in previous studies (Guo et al., 2015; Kuwano et al., 2002; Vaishya et al., 2014) . Thus, the corneal epithelial barrier should be mainly responsible for the poor aqueous humor bioavailability of TH-HNMs in normal rabbit eyes.
It is generally admitted that the epithelial cells internalize nanocarriers mainly via pinocytosis pathway which encompasses several diverse mechanisms: macropinocytosis, clathrin-mediated endocytosis (CME), caveolae-mediated endocytosis (CvME) and clathrin-and caveolae-independent endocytosis (Conner and Schmid, 2003; Pepić Fig. 8 . Concentration-time profiles of TH in rabbit corneas with de-epithelialization following topical instillation of TH-HNMs and oily TH. Bars represent ± SD (n = 5), *P < 0.05/**P < 0.01. Fig. 9 . Concentration-time profiles of TH in aqueous humor of rabbit eyes with corneal de-epithelialization following topical instillation of TH-HNMs and oily TH. Bars represent ± SD (n = 5), *P < 0.05/**P < 0.01. European Journal of Pharmaceutical Sciences 109 (2017 ) 288-296 et al., 2013 Plapied et al., 2011) . Macropinocytosis is a transient process while micropinocytosis (CME, CvME, clathrin-and caveolae-independent endocytosis) is a constitutive pathway. Generally, several endocytic mechanisms often take place simultaneously (Plapied et al., 2011) . After internalization, the nanocarriers can be included in diverse transport vesicles derived from the plasma membrane via different mechanisms. It is likely that each of these pathways fulfils unique functions in the cell and varies mechanistically not only in how the vesicles are formed, but also in terms of which cargo molecules they transport, to what intracellular destination their cargo is delivered and how their entry is regulated (Conner and Schmid, 2003) . The clathrincoated vesicles and macropinosomes will fuse with endolysosomes which can acidify the cargoes and contain a variety of enzymes, whereas caveolae-coated vesicles can escape endolysosomes and lead to direct exocytosis (Plapied et al., 2011) . In view of these, the fate of the internalized TH-NMs by corneal epithelium should be diversified. For most cell types, CME serves as the main mechanism of internalization for macromolecules or particles (Couvreur, 2009 ). The TH-NMs internalized into the clathrin-coated vesicles will be end up and release the cargoes quickly after fusing with the lysosomes because of its pH-dependent release features. Caveolae components are also expressed in many ocular cell types including the corneal epithelium and play critical roles in endocytosis and transcellular transport (Gu et al., 2017) . The internalization of hyaluronic acid-chitosan oligomer based nanoparticles by SV40-immortalized human corneal epithelial cell was already proved to be mainly via a CvME pathway (Contreras-ruiz et al., 2011) . Thus, the TH-NMs internalized into caveolae vesicles which can bypass the lysosomes would avoid being acidified and be transported into deep epithelial layers (transcytosis) or secreted out of corneal epithelium directly (exocytosis). But, in most cells, even after activation, caveolae are only slowly internalized (t 1/2 > 20 min) and the small vesicles (50-60 nm in diameter) carry little fluid-phase volume (Conner and Schmid, 2003) . It should be the main reason of the poor transcellular permeability of TH-NMs in corneal epithelium. The studies on the details of internalization of nanocarriers by corneal epithelium and the fate of the internalized cargoes have lagged behind the achievement in other cells. Thus, much work needs to be done to understand well the corneal absorption and elimination mechanisms of the nanocarriers. As shown in Fig. 8 , drug concentrations in de-epithelialized corneas treated with TH-HNMs were also significantly increased compared with oily TH at all time points. The AUC 0-360 min for TH-HNMs in the deepithelialized cornea increased 3.1-fold compared with oily TH (Table 2) . Drug concentrations in aqueous humor of most de-epithelialized eyes increased to detectable levels. The aqueous humor drug levels for TH-HNMs were also significantly increased compared with oily TH (Fig. 9) . The AUC 0-360 min for TH-HNMs in the aqueous humor of the de-epithelialized eyes increased 2.6-fold compared with oily TH (Table 3 ). These findings indicated that TH-HNMs penetrate through the corneal stroma and endothelium readily without the obstacle of the epithelial layer.
Regarding fungal keratitis, the corneal stroma where the fungi attaches, grows and proliferates is the main targeting site of antifungal drugs. It is typically more difficult to control deep fungal keratitis (Kaur et al., 2008; Tuli, 2011) . Transporting sufficient drugs into the corneal stroma should be the decisive factor for successful fungal keratitis therapy. In addition to corneal debridement before topical administration, the intrastromal injection of antifungal agents was adopted to improve the stromal drug level for the treatment of recalcitrant deep fungal keratitis (Guber et al., 2016; Kalaiselvi et al., 2015; Nejabat et al., 2016) . Thus, debridement of the ulcer is still strongly recommended before topical application of TH-HNMs for fungal keratitis. The good corneal stroma permeability of TH-HNMS should be very helpful for achieving satisfactory therapeutic effects for fugal keratitis.
Additionally, the concentrations of TH in intact corneas and deepithelialized corneas both decreased quickly after topical instillation of TH-NMs (Fig. 7 and Fig. 8) . The fast elimination of the drugs should be a consequence of the discharge of released drugs by efflux transporters (P-gp, MRP, and BCRP) and the secretion of intact micelles via exocytosis pathway. It indicated that the TH-NMs had to release the encapsulated TH quickly in cornea within a relatively limited residence time to play satisfactory therapeutic effects. The pH-dependant drug release characteristics of TH-NMs should meet this requirement well. The corneal epithelial cells, the keratocytes, the corneal endothelial cells and the accumulated phagocytes (neutrophils and macrophages) at infected site all can internalize TH-NMs and accelerate the release of encapsulated TH from micelles. Hence, the pH-sensitive carriers, temperature-sensitive carriers or carriers with other trigger mechanisms which can release drugs quickly after being absorbed and are stable during storage should be more suitable for delivering antifungal agents into cornea than the typical ocular colloidal carriers with slow release features.
Conclusions
In summary, a topically applied ophthalmic micellar preparation of TH was successfully developed based on the soft non-ionic surfactant-HS 15. The TH-loaded HS 15 micelles possessed an adequately small droplet size, good physical stability, and high entrapment efficiency and showed no signs of ocular irritation. TH-HNMs can penetrate into the corneal epithelium quickly and efficiently in mouse eyes. TH-HNMs also exhibited good permeability in corneal stroma of mouse eyes after de-epithelialization. Compared with the oily TH, TH-HNMs delivered significantly increased levels of TH into rabbit corneas with or without de-epithelialization. HS 15 micelles hold great promise as an efficient carrier of TH for the treatment of fungal keratitis. The distribution features of TH-HNMs in the mouse and rabbit corneas suggest that ulcer debridement is still recommended before the topical application of the TH-HNMs for the treatment of fungal keratitis. Further work will focus on improving the efficiency of topically applied ocular micellar carriers to penetrate through the whole epithelial layer.
